If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
336
results.
Updated on
20/08/2026 [07:44:00]
Results 50 to 75 of 336
Absstract of: EP4786984A1
The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.
Absstract of: WO2025160022A1
The presently claimed and described technology provides methods for chemiluminescence-based assays for detecting phosphorylated tau (p-tau)217 in a biological sample employing 1,2 dioxetane compounds.
Absstract of: TW202542522A
Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.
Absstract of: CN122503499A
本发明涉及生物医药技术领域，尤其是涉及基于LTF的PASC相关心血管系统症状风险评估应用。本发明提供了一种以LTF为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Absstract of: CN122506168A
本发明公开了一种基于金纳米颗粒的等离子增强荧光偶联适配体比率传感器的制备方法及其在淀粉样蛋白可视化检测中的应用。本发明制备金纳米颗粒，通过加入EDC/NHS将金纳米颗粒固定在氨基化的酶标板上；使两端分别修饰氨基和巯基的β‑淀粉样蛋白适配体形成Au‑S键接枝至金纳米颗粒修饰的酶标板；加入EDC/NHS将孟加拉玫瑰通过酰胺键接枝至金纳米颗粒上的适配体上得到以等离子体增强荧光偶联适配体作为响应荧光探针，以9‑蒽甲酸作为参比荧光制得等离子增强/比率荧光探针传感器。本发明制备的等离子增强/比率荧光探针传感器的稳定性好，实现便携式、超灵敏和特异性的β‑淀粉样蛋白可视化定量检测。
Absstract of: CN122506155A
该水产品组胺的快速检测试纸条制备及检测方法，通过测流层析的方式，以适配体为特异性识别元件，使用价格适宜、易于合成的DNA链作为基本元件解决了现有水产品组胺的检测方法存有的操作过程繁琐、特异性和稳定性弱、成本高昂的问题，特别适合水产品组胺检测使用的需要。
Absstract of: WO2025101131A1
The invention relates generally to cellular biology. In particular, the specification teaches a method of detecting and quantifying cellular biological age of a cell.
Absstract of: WO2024256685A1
The present invention relates to a modified secreted AY-WB protein 5 (SAP05) protein, and in particular the use of the modified SAP05 protein as part of a fusion compound for use in ubiquitin-independent protein degradation. The invention also relates to methods for the use of the fusion compound in targeted protein degradation, modulating physiological responses and therapy.
Absstract of: CN122487683A
0001 本发明公开了一种用于阿尔茨海默病的联检试剂盒及其应用，属于医学诊断技术领域。该试剂盒包括检测神经颗粒蛋白（NRGN）的第一检测试剂、检测β‑淀粉样蛋白42（Aβ42）的第二检测试剂和检测磷酸化tau蛋白217（p‑tau217）的第三检测试剂。本发明通过联合检测NRGN、Aβ42和p‑tau217三种标志物的水平，并依据NRGN<100 pg/mL、Aβ42<800 pg/mL、p‑tau217>0.5 pg/mL的判定规则进行综合评估，能够显著提高阿尔茨海默病诊断的灵敏度（95.8%）和特异性（92.2%），ROC曲线下面积AUC达0.956，优于任一单一标志物。本发明试剂盒以外周血、尿液和脑脊液为检测样本，无创、便捷、成本可控，适用于阿尔茨海默病的大规模筛查及临床辅助诊断。
Absstract of: CN122484279A
0001 本发明适用于生物医学及分子诊断技术领域，提供了一种腺苷酸环化酶8作为阿尔茨海默症生物标志物的应用，本发明首次发现并证实，腺苷酸环化酶8在阿尔茨海默症患者及模型小鼠的海马组织中表达水平显著升高，且其在外周血液中的表达变化与海马组织呈现高度一致性。因此，通过检测受试者血液等离体样本中腺苷酸环化酶8的表达水平，即可反映海马组织的病理改变，用于阿尔茨海默症的辅助诊断、病情评估或风险筛查。本发明突破了无法活体获取海马组织进行检测的临床限制，提供了一种无创、简便、特异性强、灵敏度高的外周血生物标志物，适用于大规模人群筛查与长期病情监测，具有显著的临床实用价值和产业化前景。
Absstract of: CN122487677A
0001 本发明提供了一种PD‑MCI标志物及其筛选方法和应用，该PD‑MCI标志物为PLEKHH2、CA1和WDR1。在本发明中通过识别的"神经连接病"机制为治疗开发开辟了新途径，而药物重定位候选药物建立了临床前验证和临床试验的明确下一步。
Absstract of: CN122484254A
本发明涉及生物检测与体外诊断技术领域，尤其涉及一种基于MS2病毒样颗粒装载DNA的蛋白质检测方法、信号报告单元及试剂盒。方法通过将带有包装位点和检测标签序列的DNA包裹于MS2病毒样颗粒内部，并对颗粒表面进行功能化修饰，使其作为信号报告单元参与靶蛋白的夹心免疫识别；在完成特异结合后，经洗涤及核酸酶去背景处理，再对颗粒内部DNA进行扩增检测，从而实现对目标蛋白的定性和/或定量分析。本发明兼具免疫识别的高特异性、核酸扩增的高灵敏度以及MS2病毒样颗粒对内部核酸的保护作用，具有背景低、抗干扰能力强、检测灵敏度高和适于复杂生物样本检测等优点，适用于Aβ1‑42等低丰度蛋白标志物的检测。
Absstract of: FR3171721A1
L’invention concerne un dispositif permettant de mesurer le niveau d'une molécule cible telle qu'une protéine dans un échantillon de fluide d'un sujet, le dispositif comprenant un composant d'échantillonnage pour prélever le fluide du sujet ; un composant de quantification pour quantifier le niveau de la protéine cible dans l'échantillon de fluide ; et un composant de transport pour transporter le fluide du composant d'échantillonnage au composant de quantification. Figure de l’abrégé : Figure 1
Absstract of: CN122483194A
本申请涉及生物医药的技术领域，具体涉及一种靶向APOE蛋白HSPG结合区的单克隆抗体或其抗原结合片段、及其应用。该单克隆抗体或其抗原结合片段包括重链可变区和轻链可变区；重链可变区包括重链互补决定区CDRH1（SEQ ID NO:3）、CDRH2（SEQ ID NO:4）以及CDRH3（SEQ ID NO:5）；轻链可变区包括轻链互补决定区CDRL1（SEQ ID NO:6）、CDRL2（SEQ ID NO:7）以及CDRL3（SEQ ID NO:8）。本申请的单克隆抗体通过特异性阻断APOE与HSPG的病理性相互作用，为阿尔茨海默病等神经退行性疾病提供了一种全新的治疗策略。
Absstract of: CN122484126A
0001 本发明公开了一种pTau231适配体、pTau231探针、电化学生物传感器及构建方法，属于生物检测技术领域，所述电化学生物传感器以pTau231适配体、pTau231探针为核心生物识别元件，结合免疫磁珠富集模块、TDT酶促信号放大模块和靶标探针诱导ZIF‑8原位生长信号放大模块构建而成，用于超灵敏检测pTau231蛋白。该电化学生物传感器结合了免疫磁珠富集、TDT酶促信号放大和ZIF‑8原位生长信号放大三大模块，实现了多重信号放大与高效信号转换，将蛋白信号转为核酸信号，再转为可测量的强电化学信号，实现了低丰度pTau231的高灵敏检测，检测线性范围宽，可达
。
Absstract of: CN122487661A
0001 本申请涉及生物检测技术领域，具体公开了一种多重数字式蛋白检测方法。本申请利用微米级亲水修饰磁珠作为模板，通过使用涡旋振荡生成均一尺寸液滴；该检测方法不需要复杂的微流控系统、芯片或仪器产生均一的液滴，操作简单，对设备依赖程度低，可在几秒内完成反应试剂的快速分割，以磁珠为模板的液滴尺寸均一。本申请可以实现磁珠高利用率，基于振荡式的磁珠液滴生成技术避免了传统数字ELISA方法中装载方式限制导致磁珠利用率低的问题，提高检测灵敏度。本申请通过磁珠的大小、荧光、颜色、形貌进行组合编码，结合基于磁珠的涡旋液滴生成技术实现了多重数字式蛋白检测方法。
Absstract of: CN122484253A
0001 本发明公开了一种基于斑马鱼评价样品激活乙醛脱氢酶功效的方法。其首先构造斑马鱼评价模型，通过酒精暴露幼鱼后检测待乙醛脱氢酶活性，若样品实验组酶活性显著高于模型组，则判定待测样品具有激活功效。本发明能在活体水平上快速、直观地评价候选物质对乙醛脱氢酶（ALDH）的激活能力，从而筛选出能够有效加速乙醛清除、减轻乙醛毒性的活性成分。
Absstract of: WO2025024817A1
Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.
Absstract of: WO2025118073A1
The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
Absstract of: CN122487652A
本发明涉及外周血血清中组织蛋白酶H在阿尔兹海默诊治中的用途，属于生物技术领域。本发明通过对CatH在AD相关样本中的表达/活性特征及其与疾病发生发展关系的研究与验证，确立血清中CatH作为AD新的诊疗靶点/生物标志物，并据此实现外周体液检测用于筛查、辅助诊断，同时为针对CatH 的抑制剂筛选与外周干预药物开发提供依据。
Absstract of: US20260219277A1
The present invention relates to a fluorescent compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof; and a composition for detecting gingipain, composition for diagnosing Porphyromonas gingivalis (P. gingivalis) infection or antibacterial composition against P. gingivalis using the same:
Absstract of: US20260218203A1
The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′ SEQ. ID. NO: 27, wherein Xu is U or absent.
Absstract of: US20260215689A1
0000 Smart glasses have an outward side and an inward side facing a user. A light source is attached to the outward side emits a light beam. One or more cameras are attached to the outward side to capture images or videos. The smart glasses include a processor, speakers, and one or more microphones that receive voice control or interactions. The smart glasses are coupled to a non-transitory computer readable medium and a smart phone or a tablet. The smart glasses interact with a multi-modal generative artificial intelligence assistant including a transformer with self-attention and position encoding layers that performs computer vision and natural language processing. The glasses may also have displays, touch sensors, memory, machine learning and gesture analysis, and the ability to recognize an object. The glasses may also be coupled to a wearable device with contact-based sensors.
Absstract of: WO2026161742A1
Methods and materials for identifying mammals (e.g., humans) as having, or being likely to have or to develop, Alzheimer's disease are provided herein. In some cases, methods and materials for stratifying mammals with Alzheimer's disease are provided herein.
Nº publicación: WO2026159152A1 30/07/2026
Applicant:
TRIMTECH THERAPEUTICS LTD [GB]
TRIMTECH THERAPEUTICS LIMITED
Absstract of: WO2026159152A1
The present invention relates to a method for identifying test molecules capable of binding an oligomeric target protein and a RING-type E3 ligase in the presence of a fusion protein, and a cell expressing said fusion protein.
BOPI
Electronic site
